Consolidation Chemotherapy
"Consolidation Chemotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY. It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.
| Descriptor ID |
D060830
|
| MeSH Number(s) |
E02.319.218
|
| Concept/Terms |
Consolidation Chemotherapy- Consolidation Chemotherapy
- Chemotherapies, Consolidation
- Chemotherapy, Consolidation
- Consolidation Chemotherapies
|
Below are MeSH descriptors whose meaning is more general than "Consolidation Chemotherapy".
Below are MeSH descriptors whose meaning is more specific than "Consolidation Chemotherapy".
This graph shows the total number of publications written about "Consolidation Chemotherapy" by people in this website by year, and whether "Consolidation Chemotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 2 | 4 |
| 2018 | 1 | 6 | 7 |
| 2019 | 3 | 3 | 6 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Consolidation Chemotherapy" by people in Profiles.
-
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2024 Sep; 11(9):e671-e681.
-
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun; 19(6):928-940.
-
Local Consolidative Therapy Versus Systemic Therapy Alone for Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):635-644.
-
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021 03 02; 325(9):833-842.
-
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 04; 68(4):e28929.
-
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291.
-
Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. J Clin Oncol. 2020 02 20; 38(6):602-612.
-
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 02 13; 382(7):597-609.
-
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755.
-
Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 01; 21(1):37-46.e7.